Frozen Shoulder News and Research

RSS

Frozen shoulder is a condition that causes pain in the shoulder, restricting movement and eventually causing the joint to stiffen up. In severe cases, movement of the shoulder may be completely restricted. Frozen shoulder is also called adhesive capsulitis or shoulder contracture.

Link between long-term hyperglycemia and upper-limb musculoskeletal conditions revealed

Study demonstrates that long-term hyperglycemia significantly increases the risk of upper-limb musculoskeletal conditions, while BMI influences the risk of carpal tunnel syndrome and Dupuytren's disease differently.

23 Jan 2024

The Parkinson's Pandemic: from the importance of early diagnosis to digital solutions

News Medical spoke to Michele Hu, Consultant Neurologist at Oxford University Hospitals and Professor of Clinical Neuroscience at the Nuffield Department of Clinical Neurosciences, University of Oxford, about prodromal Parkinson's and what the future looks like for this neurological disease.

11 Apr 2023

New findings point to specific genes linked with increased risk of frozen shoulder

Frozen shoulder, or adhesive capsulitis, is a common cause of shoulder pain and immobility. New findings point to specific genes associated with an increased risk of this condition, reports The Journal of Bone & Joint Surgery.

14 Oct 2022

Risk factors associated with shoulder surgery are low, but some need further surgery within a year

Rates of serious complications associated with shoulder surgery are low, but one in 26 patients need further surgery within a year, finds a study in The BMJ today.

7 Jul 2022

Facing COVID-19 patients on ventilators down may cause nerve damage

Some people are more likely to experience severe coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These include the elderly, people who are obese and have underlying medical conditions, such as diabetes, obesity, heart disease, lung illness, and kidney disease, among others.

14 Sep 2020

Severely ill COVID-19 patients on ventilators can experience permanent nerve damage

Severely ill COVID-19 patients on ventilators are placed in a prone (face down) position because it's easier for them to breathe and reduces mortality.

12 Sep 2020

New nonsurgical treatment reduces pain, improves function in patients with "frozen shoulder"

A new nonsurgical treatment decreases errant blood flow in the shoulder to quickly reduce pain and improve function in patients with adhesive capsulitis, also known as "frozen shoulder,"

15 Jun 2020

Decompression surgery may offer no additional benefit for people with shoulder impingement

Decompression surgery does not reduce shoulder pain any more than placebo surgery for people with shoulder impingement – when the tendon rubs and catches in the joint, according to the first placebo-controlled trial in shoulder surgery published in The Lancet.

22 Nov 2017

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

14 Mar 2016

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that Asahi Kasei Pharma Corporation has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan.

20 Jul 2015

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2014 and provided a corporate update.

13 Mar 2015

Orthopedic surgeons recommend prompt medical attention for shoulder dislocations

Prompt and appropriate treatment of a dislocated shoulder--when the head of the upper arm bone (humerus) is completely knocked out of the shoulder socket (glenoid)--can minimize risk for future dislocations as well as the effects of related bone, muscle and nerve injuries, according to a literature review appearing in the December issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).

2 Dec 2014

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014.

20 Nov 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014.

30 Oct 2014

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.

9 Oct 2014

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.

21 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.

7 Aug 2014

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT.

26 Jun 2014